Fortress Biotech, Inc. Earnings Per Share (Basic)
Fortress Biotech, Inc. (FBIO) reported Earnings Per Share (Basic) of -$0.08 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-13
- Fortress Biotech, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.08, a 116.00% decline year-over-year.
- Fortress Biotech, Inc. earnings per share, basic for the quarter ending 2026-03-31 was $3.44.
- Fortress Biotech, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.20.
- Fortress Biotech, Inc. earnings per share, basic for the quarter ending 2025-09-30 was $0.13.
- Fortress Biotech, Inc. earnings per share, basic for fiscal 2025 was -$0.07.
- Fortress Biotech, Inc. earnings per share, basic for fiscal 2024 was -$2.69.
- Fortress Biotech, Inc. earnings per share, basic for fiscal 2023 was -$8.47.
- Fortress Biotech, Inc. earnings per share, basic for fiscal 2022 was -$15.97.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.08 10-Q · filed 2026-08-13 | $3.34 10-Q · filed 2026-08-13 | $3.19 derived: net income ÷ weighted average shares · filed 2026-08-13 | $3.42 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2026-03-31 | $3.44 10-Q · filed 2026-05-14 | $3.30 derived: net income ÷ weighted average shares · filed 2026-05-14 | $3.56 derived: net income ÷ weighted average shares · filed 2026-05-14 | $4.11 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-12-31 | -$0.20 derived: net income ÷ weighted average shares · filed 2026-03-31 | -$0.09 derived: net income ÷ weighted average shares · filed 2026-03-31 | $0.38 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.07 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | $0.13 10-Q · filed 2025-11-14 | $0.63 derived: net income ÷ weighted average shares · filed 2026-08-13 | $0.16 10-Q · filed 2025-11-14 | -$0.20 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-06-30 | $0.50 10-Q · filed 2026-08-13 | $0.02 10-Q · filed 2026-08-13 | -$0.34 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.97 derived: net income ÷ weighted average shares · filed 2026-08-13 | ||||
| 2025-03-31 | -$0.48 10-Q · filed 2026-05-14 | -$0.85 derived: net income ÷ weighted average shares · filed 2026-05-14 | -$1.56 derived: net income ÷ weighted average shares · filed 2026-05-14 | -$2.24 derived: net income ÷ weighted average shares · filed 2026-05-14 | ||||
| 2024-12-31 | -$0.37 derived: net income ÷ weighted average shares · filed 2026-03-31 | -$1.08 derived: net income ÷ weighted average shares · filed 2026-03-31 | -$1.78 derived: net income ÷ weighted average shares · filed 2026-03-31 | -$2.69 10-K · filed 2026-03-31 | ||||
| 2024-09-30 | -$0.76 10-Q · filed 2025-11-14 | -$1.49 derived: net income ÷ weighted average shares · filed 2025-11-14 | -$2.43 10-Q · filed 2025-11-14 | -$3.49 derived: net income ÷ weighted average shares · filed 2025-11-14 | ||||
| 2024-06-30 | -$0.73 10-Q · filed 2025-08-14 | -$1.76 10-Q · filed 2025-08-14 | -$2.76 derived: net income ÷ weighted average shares · filed 2025-08-14 | -$3.69 derived: net income ÷ weighted average shares · filed 2025-08-14 | ||||
| 2024-03-31 | -$1.04 10-Q · filed 2025-05-15 | -$1.03 10-Q · filed 2024-05-15 | -$2.09 derived: net income ÷ weighted average shares · filed 2025-05-15 | -$3.07 derived: net income ÷ weighted average shares · filed 2025-05-15 | -$5.90 derived: net income ÷ weighted average shares · filed 2025-05-15 | |||
| 2023-12-31 | -$1.05 derived: net income ÷ weighted average shares · filed 2025-03-31 | -$2.01 derived: net income ÷ weighted average shares · filed 2025-03-31 | -$5.30 derived: net income ÷ weighted average shares · filed 2025-03-31 | -$8.47 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | -$0.94 10-Q · filed 2024-11-14 | -$4.57 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$7.94 10-Q · filed 2024-11-14 | -$12.48 derived: net income ÷ weighted average shares · filed 2024-11-14 | ||||
| 2023-06-30 | -$3.65 10-Q · filed 2024-08-13 | -$0.24 10-Q · filed 2023-08-14 | -$7.14 10-Q · filed 2024-08-13 | -$0.47 10-Q · filed 2023-08-14 | -$11.79 derived: net income ÷ weighted average shares · filed 2024-08-13 | -$15.88 derived: net income ÷ weighted average shares · filed 2024-08-13 | ||
| 2023-03-31 | -$3.47 10-Q · filed 2024-05-15 | -$0.21 10-Q · filed 2023-05-15 | -$8.18 derived: net income ÷ weighted average shares · filed 2024-05-15 | -$12.29 derived: net income ÷ weighted average shares · filed 2024-05-15 | -$3.73 derived: net income ÷ weighted average shares · filed 2024-05-15 | |||
| 2022-12-31 | -$4.79 derived: net income ÷ weighted average shares · filed 2024-03-28 | -$8.91 derived: net income ÷ weighted average shares · filed 2024-03-28 | -$2.29 derived: net income ÷ weighted average shares · filed 2024-03-28 | -$15.97 10-K · filed 2024-03-28 | -$0.97 10-K · filed 2023-03-31 | |||
| 2022-09-30 | -$4.11 10-Q · filed 2023-11-14 | -$0.25 10-Q · filed 2022-11-14 | -$1.01 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$11.15 10-Q · filed 2023-11-14 | -$0.68 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | -$0.26 10-Q · filed 2023-08-14 | -$0.24 10-Q · filed 2022-08-11 | -$0.47 10-Q · filed 2023-08-14 | -$0.42 10-Q · filed 2022-08-11 | ||||
| 2022-03-31 | -$0.21 10-Q · filed 2023-08-14 | -$0.18 10-Q · filed 2022-05-12 | ||||||
| 2021-12-31 | -$0.79 10-K · filed 2023-03-31 | |||||||
| 2021-09-30 | -$0.26 10-Q · filed 2022-11-14 | -$0.41 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | -$0.04 10-Q · filed 2022-08-11 | -$0.15 10-Q · filed 2022-08-11 | ||||||
| 2021-03-31 | -$0.11 10-Q · filed 2022-05-12 | |||||||
| 2020-03-31 | -$0.19 10-Q · filed 2020-05-11 | |||||||
| 2019-03-31 | $0.03 10-Q · filed 2020-05-11 | |||||||
| 2018-03-31 | -$0.49 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |